Bile Duct Neoplasms Malignant — Stenting Malignant Jaundice for Quality of Life
Citation(s)
Abraham NS, Barkun JS, Barkun AN Palliation of malignant biliary obstruction: a prospective trial examining impact on quality of life. Gastrointest Endosc. 2002 Dec;56(6):835-41.
Brucker PS, Yost K, Cashy J, Webster K, Cella D General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof. 2005 Jun;28(2):192-211. Erratum in: Eval Health Prof. 2005 Sep;28(3):370.
Cella D, Hahn EA, Dineen K Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res. 2002 May;11(3):207-21.
Cheung YB, Goh C, Thumboo J, Khoo KS, Wee J Variability and sample size requirements of quality-of-life measures: a randomized study of three major questionnaires. J Clin Oncol. 2005 Aug 1;23(22):4936-44.
Cotton PB, Schmitt C Quality of Life in palliative management of malignant obstructive jaundice. Scand J Gastroenterol Suppl. 1993;199:44-6.
Fairclough DL, Cella DF Functional Assessment of Cancer Therapy (FACT-G): non-response to individual questions. Qual Life Res. 1996 Jun;5(3):321-9.
Fitzsimmons D, Johnson CD Quality of life after treatment of pancreatic cancer. Langenbecks Arch Surg. 1998 Apr;383(2):145-51. Review.
Frakes JT, Johanson JF, Stake JJ Optimal timing for stent replacement in malignant biliary tract obstruction. Gastrointest Endosc. 1993 Mar-Apr;39(2):164-7.
Giorgio PD, Luca LD Comparison of treatment outcomes between biliary plastic stent placements with and without endoscopic sphincterotomy for inoperable malignant common bile duct obstruction. World J Gastroenterol. 2004 Apr 15;10(8):1212-4.
Jaeschke R, Singer J, Guyatt GH Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989 Dec;10(4):407-15.
Jemal A, Thomas A, Murray T, Thun M Cancer statistics, 2002. CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47. Erratum in: CA Cancer J Clin 2002 Mar-Apr;52(2):119. CA Cancer J Clin 2002 May-Jun;52(3):181-2.
Jiang WG, Puntis MC Immune dysfunction in patients with obstructive jaundice, mediators and implications for treatments. HPB Surg. 1997;10(3):129-42. Review.
Johanson JF, Schmalz MJ, Geenen JE Incidence and risk factors for biliary and pancreatic stent migration. Gastrointest Endosc. 1992 May-Jun;38(3):341-6.
Kramer HJ Impaired renal function in obstructive jaundice: roles of the thromboxane and endothelin systems. Nephron. 1997;77(1):1-12. Review. Erratum in: Nephron 1998;78(1):124.
Moss AC, Morris E, Leyden J, MacMathuna P Malignant distal biliary obstruction: a systematic review and meta-analysis of endoscopic and surgical bypass results. Cancer Treat Rev. 2007 Apr;33(2):213-21. Epub 2006 Dec 8. Review.
Rege RV Adverse effects of biliary obstruction: implications for treatment of patients with obstructive jaundice. AJR Am J Roentgenol. 1995 Feb;164(2):287-93. Review.
Steel JL, Eton DT, Cella D, Olek MC, Carr BI Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. Ann Oncol. 2006 Feb;17(2):304-12. Epub 2005 Dec 15.
Webster K, Cella D, Yost K The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes. 2003 Dec 16;1:79. Review.
Yeoh KG, Zimmerman MJ, Cunningham JT, Cotton PB Comparative costs of metal versus plastic biliary stent strategies for malignant obstructive jaundice by decision analysis. Gastrointest Endosc. 1999 Apr;49(4 Pt 1):466-71.
Yost KJ, Sorensen MV, Hahn EA, Glendenning GA, Gnanasakthy A, Cella D Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument. Value Health. 2005 Mar-Apr;8(2):117-27.
Endoscopic Palliation of Malignant Biliary Tract Obstruction: Emphasis on Improvement in Quality of Life
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
